Spread the love“`html In a competitive job market, especially in the tech industry, having a standout resume is crucial. With hiring processes becoming more stringent, tech job seekers must leverage ...

New benchmarks show semantic code graphs helping coding agents find change locations faster and complete updates more ...

The compiler infers, but does not take instructions. There is no syntax for explicit type declarations yet, and the new type ...

The US Supreme Court ruled yesterday, June 4, that pharmaceutical company Hikma’s generic cardiovascular drug does not infringe global biopharmaceutical company Amarin’s patents covering its drug ...

A unanimous Supreme Court reversed the Federal Circuit and held that Amarin did not plausibly allege that Hikma’s skinny label and marketing actively induced infringement of Vascepa’s ...

Each day, millions of people pick up a prescription drug from their local pharmacy or mailbox. Most are affordable, with co-pays on average less than $7 for 90% of drugs. But for a growing number of ...

Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...

The Trump administration has expanded TrumpRx to include more than 600 generic medications — a significant scale-up from the platform’s original focus on branded drugs under most-favored-nation ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

WASHINGTON, April 29 (Reuters) - The U.S. Supreme Court on Wednesday heard a patent dispute over a generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular drug Vascepa that could ...

A Supreme Court case heard this week could give brand-name drugmakers longer monopolies, delay generic competition, and leave patients paying higher prices. When it comes to generic medications, ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has recommended granting a marketing authorisation for Palbociclib Viatris (palbociclib, Viatris Limited) for the ...